Product Description
Prostaglandin E2. Fate Therapeutics is developing FT1050 to improve the overall efficiency of hematopoietic stem cell (HSC) support by enhancing HSC homing to and proliferation in the bone marrow. (Sourced from: https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-emerging-data-proof-concept-ft1050)
Mechanisms of Action: Stem Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fate
Company Location: SAN DIEGO CA 92131
Company CEO: J. Scott Wolchko
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Lymphocytic Chronic B-Cell Leukemia|Chronic Myeloid Leukemia|Chronic Lymphoid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| FT1050-02 | P1 |
Completed |
Chronic Lymphoid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Acute Myeloid Leukemia |
2013-10-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|